Methyl 4'-[[2-n-propyl-4-methyl-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl]methyl]biphenyl-2-carboxylate

CAS: 528560-93-2

Ref. 3D-FM25429

Información del producto

• Nombre: Methyl 4'-[[2-n-propyl-4-methyl-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl]methyl]biphenyl-2-carboxylate
• Sinónimos: 4'-[(1,4'-Dimethyl-2'-propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid methyl ester, 4'-[(1,4'-Dimethyl-2'-propyl[2,6'-bi-1H-benzimidazole]-1'-yl)methyl]-1,1'-biphenyl-2-carboxylic acid methyl ester, Execute Standard, Methyl 4′-[[2-propyl-4-methyl-6-(1-methylbenzimidazol-2-yl)benzimidazol-1-yl]methyl]biphenyl-2-carboxylate, Telmisartan methy ester, [1,1′-Biphenyl]-2-carboxylic acid, 4′-[(1,4′-dimethyl-2′-propyl[2,6′-bi-1H-benzimidazol]-1′-yl)methyl]-, methyl ester, methyl 4'-[(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl]biphenyl-2-carboxylate
• CAS: 528560-93-2

Descripción

Methyl 4'-[[2-n-propyl-4-methyl-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl]methyl]biphenyl-2-carboxylate is an organic compound with a molecular formula of C21H19NO4. It is also known as MMBC, which stands for methyl 4'-[[2-[(N,N-dimethylamino)methyl]-6-(1,3,5,7--tetramethylbenzimidazolium)benzimidazolium]methyl]biphenyl 2'-carboxylate. MMBC is a programmed multipurpose drug that can be used to treat different types of bacterial infections. The drug was developed by the company Novartis and has been in development since 1999. MMBC has been shown to be effective against methicillin resistant Staphylococ

• Marca: Biosynth

Propiedades químicas

• Peso molecular: 528.64 g/mol
• Fórmula: C₃₄H₃₂N₄O₂
• Pureza: Min. 95%
• InChI: InChI=1S/C34H32N4O2/c1-5-10-31-36-32-22(2)19-25(33-35-28-13-8-9-14-29(28)37(33)3)20-30(32)38(31)21-23-15-17-24(18-16-23)26-11-6-7-12-27(26)34(39)40-4/h6-9,11-20H,5,10,21H2,1-4H3
• Clave InChI: InChIKey=HJCCZIABCSDUPE-UHFFFAOYSA-N
• SMILES: CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)OC)cc1